vs
艾伯维（ABBV）与908 Devices Inc.（MASS）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是908 Devices Inc.的956.2倍（$16.6B vs $17.4M）。908 Devices Inc.净利率更高（24.0% vs 10.9%，领先13.1%）。908 Devices Inc.同比增速更快（21.2% vs 10.0%）。艾伯维自由现金流更多（$4.9B vs $1.3M）。过去两年908 Devices Inc.的营收复合增速更高（53.0% vs 16.2%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
908 Devices Inc.是一家专注于研发、生产高性能便携式质谱分析设备及相关解决方案的科技企业，产品覆盖生命科学研究、生物制药制造、公共安全、法医鉴定、工业过程监测等领域，服务全球科研机构、制药企业及政府部门客户。
ABBV vs MASS — 直观对比
营收规模更大
ABBV
是对方的956.2倍
$17.4M
营收增速更快
MASS
高出11.1%
10.0%
净利率更高
MASS
高出13.1%
10.9%
自由现金流更多
ABBV
多$4.9B
$1.3M
两年增速更快
MASS
近两年复合增速
16.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $17.4M |
| 净利润 | $1.8B | $4.2M |
| 毛利率 | 72.6% | 52.7% |
| 营业利润率 | 27.3% | 17.8% |
| 净利率 | 10.9% | 24.0% |
| 营收同比 | 10.0% | 21.2% |
| 净利润同比 | 8354.5% | 121.5% |
| 每股收益（稀释后） | $1.02 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVMASS
| Q4 25 | $16.6B | $17.4M | ||
| Q3 25 | $15.8B | $14.0M | ||
| Q2 25 | $15.4B | $13.0M | ||
| Q1 25 | $13.3B | $11.8M | ||
| Q4 24 | $15.1B | $14.3M | ||
| Q3 24 | $14.5B | $14.5M | ||
| Q2 24 | $14.5B | $11.5M | ||
| Q1 24 | $12.3B | $7.4M |
净利润ABBVMASS
| Q4 25 | $1.8B | $4.2M | ||
| Q3 25 | $186.0M | $-15.0M | ||
| Q2 25 | $938.0M | $-13.3M | ||
| Q1 25 | $1.3B | $43.6M | ||
| Q4 24 | $-22.0M | $-19.4M | ||
| Q3 24 | $1.6B | $-29.3M | ||
| Q2 24 | $1.4B | $-12.5M | ||
| Q1 24 | $1.4B | $-10.9M |
毛利率ABBVMASS
| Q4 25 | 72.6% | 52.7% | ||
| Q3 25 | 66.4% | 52.5% | ||
| Q2 25 | 71.8% | 48.9% | ||
| Q1 25 | 70.0% | 47.0% | ||
| Q4 24 | 70.9% | 46.5% | ||
| Q3 24 | 70.9% | 53.6% | ||
| Q2 24 | 70.9% | 53.8% | ||
| Q1 24 | 66.7% | 52.4% |
营业利润率ABBVMASS
| Q4 25 | 27.3% | 17.8% | ||
| Q3 25 | 12.1% | -116.6% | ||
| Q2 25 | 31.7% | -116.3% | ||
| Q1 25 | 28.0% | -93.6% | ||
| Q4 24 | -9.9% | -116.8% | ||
| Q3 24 | 26.5% | -168.7% | ||
| Q2 24 | 27.6% | -74.5% | ||
| Q1 24 | 22.7% | -102.5% |
净利率ABBVMASS
| Q4 25 | 10.9% | 24.0% | ||
| Q3 25 | 1.2% | -107.0% | ||
| Q2 25 | 6.1% | -102.1% | ||
| Q1 25 | 9.6% | 370.2% | ||
| Q4 24 | -0.1% | -135.6% | ||
| Q3 24 | 10.8% | -201.8% | ||
| Q2 24 | 9.5% | -109.5% | ||
| Q1 24 | 11.1% | -147.1% |
每股收益（稀释后）ABBVMASS
| Q4 25 | $1.02 | $0.09 | ||
| Q3 25 | $0.10 | $-0.41 | ||
| Q2 25 | $0.52 | $-0.37 | ||
| Q1 25 | $0.72 | $1.23 | ||
| Q4 24 | $-0.03 | $-0.58 | ||
| Q3 24 | $0.88 | $-0.84 | ||
| Q2 24 | $0.77 | $-0.37 | ||
| Q1 24 | $0.77 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $113.0M |
| 总债务越低越好 | $58.9B | — |
| 股东权益账面价值 | $-3.3B | $143.7M |
| 总资产 | $134.0B | $190.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABBVMASS
| Q4 25 | $5.3B | $113.0M | ||
| Q3 25 | $5.7B | $112.1M | ||
| Q2 25 | $6.5B | $118.6M | ||
| Q1 25 | $5.2B | $124.3M | ||
| Q4 24 | $5.6B | $69.6M | ||
| Q3 24 | $7.3B | $71.7M | ||
| Q2 24 | $13.2B | $77.4M | ||
| Q1 24 | $18.1B | $134.2M |
总债务ABBVMASS
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | — | ||
| Q2 25 | $63.0B | — | ||
| Q1 25 | $64.5B | — | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVMASS
| Q4 25 | $-3.3B | $143.7M | ||
| Q3 25 | $-2.6B | $136.3M | ||
| Q2 25 | $-183.0M | $148.8M | ||
| Q1 25 | $1.4B | $159.4M | ||
| Q4 24 | $3.3B | $114.6M | ||
| Q3 24 | $6.0B | $131.0M | ||
| Q2 24 | $6.8B | $156.4M | ||
| Q1 24 | $8.0B | $156.9M |
总资产ABBVMASS
| Q4 25 | $134.0B | $190.1M | ||
| Q3 25 | $133.9B | $190.9M | ||
| Q2 25 | $137.2B | $191.7M | ||
| Q1 25 | $136.2B | $196.0M | ||
| Q4 24 | $135.2B | $159.5M | ||
| Q3 24 | $143.4B | $178.3M | ||
| Q2 24 | $141.9B | $208.8M | ||
| Q1 24 | $148.9B | $189.8M |
负债/权益比ABBVMASS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 45.44× | — | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $1.3M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | $1.3M |
| 自由现金流率自由现金流/营收 | 29.4% | 7.6% |
| 资本支出强度资本支出/营收 | 2.0% | 0.0% |
| 现金转化率经营现金流/净利润 | 2.87× | 0.32× |
| 过去12个月自由现金流最近4个季度 | $17.8B | $-24.7M |
8季度趋势，按日历期对齐
经营现金流ABBVMASS
| Q4 25 | $5.2B | $1.3M | ||
| Q3 25 | $7.0B | $-4.2M | ||
| Q2 25 | $5.2B | $-5.8M | ||
| Q1 25 | $1.6B | $-15.0M | ||
| Q4 24 | $7.0B | $-2.2M | ||
| Q3 24 | $5.4B | $-5.6M | ||
| Q2 24 | $2.3B | $-13.0M | ||
| Q1 24 | $4.0B | $-9.4M |
自由现金流ABBVMASS
| Q4 25 | $4.9B | $1.3M | ||
| Q3 25 | $6.6B | $-4.9M | ||
| Q2 25 | $4.9B | $-5.9M | ||
| Q1 25 | $1.4B | $-15.2M | ||
| Q4 24 | $6.8B | $-2.4M | ||
| Q3 24 | $5.2B | $-5.8M | ||
| Q2 24 | $2.0B | $-13.7M | ||
| Q1 24 | $3.8B | $-10.3M |
自由现金流率ABBVMASS
| Q4 25 | 29.4% | 7.6% | ||
| Q3 25 | 42.1% | -34.9% | ||
| Q2 25 | 31.7% | -45.3% | ||
| Q1 25 | 10.5% | -128.9% | ||
| Q4 24 | 44.7% | -17.0% | ||
| Q3 24 | 35.9% | -39.7% | ||
| Q2 24 | 14.0% | -119.4% | ||
| Q1 24 | 31.3% | -138.2% |
资本支出强度ABBVMASS
| Q4 25 | 2.0% | 0.0% | ||
| Q3 25 | 2.4% | 4.9% | ||
| Q2 25 | 1.7% | 0.9% | ||
| Q1 25 | 1.8% | 1.4% | ||
| Q4 24 | 1.9% | 1.3% | ||
| Q3 24 | 1.7% | 1.1% | ||
| Q2 24 | 1.7% | 5.6% | ||
| Q1 24 | 1.6% | 12.2% |
现金转化率ABBVMASS
| Q4 25 | 2.87× | 0.32× | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | -0.34× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
MASS
| Products | $14.3M | 82% |
| Services | $3.0M | 18% |
